PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthresbiomed central web sitesearch.manuscript submission.see also journal with issn 1478-6354registration.reference to the article.journal front page.
 
Arthritis Res. 2001; 3(Suppl A): P084.
Published online Jan 26, 2001. doi:  10.1186/ar253
PMCID: PMC3273222
Antibodies to beta2-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity
J Zabek,1 S Luft,1 T Reshetniak,2 Z Alekberowa,2 B Wojciechowska,1 W Karlik,3 and V Nasonowa2
1Institute of Rheumatology, Warsaw, Poland
2Institute of Rheumatology, Moscow, Russia
3Warsaw Agricultural University, Warsaw, Poland
Supplement
21st European Workshop for Rheumatology Research
Conference
21st European Workshop for Rheumatology Research
1-4 March 2001
Vienna, Austria
Received January 15, 2001
 
Antibodies to β2-glycoprotein I /β2-GP I/, prothrombin /Pt/ and antithrombin III /AT III/ are not strictly speaking antiphospholipid antibodies, but they are closely associated with this pool of antibodies. The "marker" and prognostic significance of these antibodies have been recently widely discussed.
The aim of the presented study was to determine whether the anti-β2-glycoprotein I, anti-Pt and anti-AT III antibodies possess "marker" and prognostic value in APS syndrome.
The presence of the serum antibodies to these serum proteins, six selected phospholipids /including cardiolipin/ and Lupus antycoag-ulant have been tested and correlated with such clinical manifestations of the antiphospholipid syndrome /APS/ like: thrombotic events, fetal loss, trombocytopenia and livedo reticularis. The study covers 83 sera of the patients with various diagnoses /in 11 SLE, 43 SLE + APS /SAPS/ and 29 in PAPS/. The antibodies to β2-glycoprotein I in 21% of the SAPS cases and in 24% of the PAPS cases have been found and in none of the SLE without APS syndrome sera. The antibodies to Pt are present in 20% and to AT III in 15% of the tested sera. The correlation of antibodies to negatively charged phospholipid, LAC and anti-β2-glycoprotein I seems to be evident. Also significant increasing of the frequency of the appearance of selected clinical manifestations in the group of the anti-β2-glycoprotein I, anti-Pt and anti-AT III - positive sera was observed, especially fetal loss, livedo reticularis and thrombocytopenia. It seems to us the anti-β2-glycoprotein I, anti-Pt and anti-AT III antibodies are very promising "marker" for APS and possess also prognostic value.
Articles from Arthritis Research are provided here courtesy of
BioMed Central